Pharma Focus Asia

OncoDNA presents the OncoDEEP genomic kit for the study of solid tumors at ESMO

Monday, September 12, 2022

OncoDNA , a genomics and theranostics (therapy and diagnosis) company specialized in precision medicine for the treatment of patients with cancer and genetic diseases, has presented its OncoDEEP kit for the study of solid tumors, at the Congress of the European Society of Medical Oncology (ESMO), which is taking place in Paris from September 9 to 13.

This tool offers an NGS (Next-Generation Sequencing) solution so that laboratories can carry out much more complete tests based on the study of biomarkers. In this way, more information can be provided to oncologists so that they can determine which is the most appropriate treatment for each of their patients, in a much more precise and personalized way.

“The kit integrates reagents and quality control standards for the sequencing of more than 600 cancer biomarkers. In addition, it includes the data analysis and clinical interpretation tools of OncoDNA to obtain a rapid analysis and a report of the molecular profile of the patient's tumor” , says Adriana Terrádez, director of OncoDNA for Spain and Portugal.

The solution is optimized for the reliable analysis of somatic variants and translocations, while facilitating the analysis of various complex signatures, such as homologous recombination deficiency (HRD), a predictive biomarker to assess the use of PARP inhibitor therapies. In addition, the kit allows measurement of tumor mutational burden (TMB), microsatellite instability (MSI), and loss of heterozygosity (LOH).

Compared to other single biomarker tests, the OncoDEEP kit encompasses a broad panel of genes and phenotypes associated with cancer therapies. An approach used to determine whether a patient may respond to specific drugs, already approved or in clinical trials, with a single test.

support tools

The OncoDEEP kit incorporates the enrichment and library preparation solutions of Twist Bioscience, an organization specialized in the study of DNA through the use of NGS located in San Francisco (USA). An alliance that has served to improve the exhaustiveness of the studies carried out and that helps laboratories to expand their bioinformatics capacities in a simple way, being able to carry out the sequencing of large panels, obtain the molecular characterization of a tumor and analyze raw data .

Also access extensive quality controls using MERCURY, OncoDNA's cloud-hosted software tool that ensures the security of recorded data. The differential is the patented OncoDNA database, located on the OncoKDM online platform, from which it is possible to extract specific clinical interpretation reports for each patient. This curated database has some 4.5 million genetic variants, 1,150 anticancer drugs, and data from 7,000 oncology clinical trials.

"We believe that this decentralized version of OncoDEEP is going to be an attractive proposition for many hospitals, as it will allow specialists to make decisions among a broader set of treatment options for their patients, saving time and outsourcing costs," says Adriana Terradez.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024